Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2030 earnings per share estimates for shares of Immunovant in a research note issued to investors on Thursday, May 29th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of $1.06 for the year. The consensus estimate for Immunovant's current full-year earnings is ($2.69) per share.
IMVT has been the topic of several other reports. HC Wainwright reiterated a "buy" rating and set a $51.00 target price on shares of Immunovant in a report on Wednesday, March 19th. Guggenheim reiterated a "buy" rating on shares of Immunovant in a report on Thursday, March 20th. Jefferies Financial Group started coverage on Immunovant in a report on Monday, March 3rd. They set a "hold" rating and a $20.00 target price on the stock. UBS Group reiterated a "neutral" rating and set a $17.00 target price (down from $38.00) on shares of Immunovant in a report on Tuesday, April 22nd. Finally, Bank of America dropped their price objective on Immunovant from $38.00 to $33.00 and set a "buy" rating on the stock in a report on Thursday, March 20th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Immunovant presently has a consensus rating of "Moderate Buy" and an average target price of $38.33.
View Our Latest Research Report on Immunovant
Immunovant Stock Performance
Shares of NASDAQ:IMVT traded up $0.68 during mid-day trading on Monday, hitting $16.02. 1,885,615 shares of the company traded hands, compared to its average volume of 1,198,220. The firm has a market cap of $2.74 billion, a P/E ratio of -6.11 and a beta of 0.61. Immunovant has a 52-week low of $12.72 and a 52-week high of $34.47. The firm's 50 day simple moving average is $14.82 and its 200 day simple moving average is $20.24.
Immunovant (NASDAQ:IMVT - Get Free Report) last announced its earnings results on Thursday, May 29th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.08. The company had revenue of $0.16 million for the quarter. During the same quarter in the prior year, the firm posted ($0.52) EPS.
Insiders Place Their Bets
In other news, CEO Peter Salzmann sold 28,094 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $12.99, for a total value of $364,941.06. Following the completion of the sale, the chief executive officer now directly owns 1,186,512 shares in the company, valued at approximately $15,412,790.88. The trade was a 2.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Andrew J. Fromkin sold 8,000 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $19.60, for a total value of $156,800.00. Following the completion of the sale, the director now owns 91,913 shares of the company's stock, valued at $1,801,494.80. This trade represents a 8.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,682 shares of company stock worth $753,419 in the last three months. 5.90% of the stock is owned by insiders.
Institutional Investors Weigh In On Immunovant
Institutional investors have recently made changes to their positions in the company. Strs Ohio bought a new stake in shares of Immunovant in the 1st quarter valued at approximately $27,000. FNY Investment Advisers LLC bought a new stake in shares of Immunovant in the 1st quarter valued at approximately $34,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Immunovant in the 1st quarter valued at approximately $37,000. Headlands Technologies LLC bought a new stake in shares of Immunovant in the 1st quarter valued at approximately $51,000. Finally, Covestor Ltd increased its holdings in shares of Immunovant by 187.5% in the 1st quarter. Covestor Ltd now owns 3,764 shares of the company's stock valued at $64,000 after acquiring an additional 2,455 shares during the last quarter. 47.08% of the stock is currently owned by institutional investors.
About Immunovant
(
Get Free Report)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Further Reading
Before you consider Immunovant, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.
While Immunovant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
